Retinitis Pigmentosa
Interventions of Interest For questions please contact Madeline Booth, Program Manager, mbooth@icer.org. View the Key Stakeholder List.
Program Type: New England CEPAC
Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
Interventions of Interest The independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for tabelecleucel when compared to usual care; tabelecleucel would achieve common thresholds for cost-effectiveness if priced between $143,900 to $273,700 per treatment cycle. Final Documents For questions or to request a Spanish translated Report-at-a-Glance or ICER […]
Rishi Wadhera, MD, MPP, MPhil
Joseph Ross, MD, MHS
Josephine Porter, MPH
Julie Kueppers, PhD, NP
Maria Kefalas, PhD, MA
Post-Traumatic Stress Disorder
Interventions of Interest Independent appraisal committee voted that current evidence is not adequate to demonstrate superior net health benefits for MDMA-AP compared to short-term trauma-focused psychotherapies. Click here for “Five Fast Facts on ICER and our PTSD Report.” For questions or to request a Spanish translated Report-at-a-Glance or ICER Snapshot for this assessment, please contact info@icer.org. […]
Schizophrenia
Interventions of Interest: The independent appraisal committee voted that current evidence is not adequate to demonstrate superior net health benefits for KarXT compared to generically available aripiprazole. If long-term data confirm KarXT’s benefits and lack of weight gain, it would achieve common thresholds for cost-effectiveness if priced between $16,000 to $20,000 per year. Final Documents […]